Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE versus ETHRIL 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE versus ETHRIL 250.
ERYTHROMYCIN ETHYLSUCCINATE vs ETHRIL 250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin ethylsuccinate is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also have anti-inflammatory and immunomodulatory effects.
ETHRIL 250 (valproate semisodium) increases GABA levels in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, enhancing neuronal inhibition.
400-800 mg orally every 6 hours or 4 times daily; maximum 4 g/day. Intravenous form available but ethylester is oral only.
250 mg orally every 8 hours, or 500 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in adults with normal renal function; extended to 5-6 hours in patients with severe hepatic impairment; not significantly altered by renal failure.
Terminal elimination half-life of 6-8 hours in adults; prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily hepatic metabolism and biliary excretion (80-90% as unchanged drug and metabolites into bile); renal excretion accounts for 5-15% of unchanged drug; fecal elimination of unabsorbed drug.
Primarily renal elimination (70-80% unchanged), with 10-15% biliary/fecal elimination as metabolites; total clearance approximates 150 mL/min.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic